A U.S. court has denied a request by India's Ranbaxy Laboratories to stop competitors from launching generic copies of AstraZeneca's heartburn pill Nexium and Roche's antiviral, Valcyte.
Last week, Ranbaxy sued the U.S. FDA for revoking approvals granted to launch generic copies of AstraZeneca's Nexium and Roche's Valcyte.
Ranbaxy had also sought to prevent Endo International and Dr Reddy's from making their own generic versions of Valcyte after the FDA gave the two companies final approvals.
According to the court filing, Ranbaxy's request was denied by U.S. District Judge Beryl Howell in Minneapolis.
Read the Reuters press release